Rockville, MD – July 3, 2018 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it has been invited to present preliminary results from proof of concept studies of its lead product, the MVM-MVP Kit, at Cambridge Health Institute’s (CHI) annual BioProcess Summit on August 13-17, 2018 in Boston, MA.
A poster displaying the results will be available for viewing throughout the conference and an oral presentation will be given by MockV CEO – David Cetlin – on Friday, August 17, 2018 at 3:00 pm in the Detection, Characterization and Control of Process-and Product-Related Impurities track. The presentation and poster will explore the practicality and accuracy of predicting Minute Virus of Mice removal through a non-infecitous Mock Virus Particle (MVP).
Poster and Oral Presentation Titles:
- Predicting MVM Clearance by Nanofiltration and Anion Exchange Chromatography Using a Non-Infectious “Mock Virus Particle
About CHI’s BioProcessing Summit
The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today’s bioprocess challenges. Now in its tenth year, the event has grown to include 17 distinct conferences with weeklong programming on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing. Along with the impressive array of conferences, the Summit also includes short courses and training seminars that provide in-depth coverage of critical bioprocess topics. More details about the conference can be found at https://www.bioprocessingsummit.com/
About MockV Solutions Inc.
MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactive virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging “spiking studies”. The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements – jeopardizing the timely approval of potentially life-altering therapies. MockV’s lead product candidate, the MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution.
For further information regarding MockV Solutions, Inc., please visit the Company’s website at www.mockvsolutions.com.